Purple Biotech (PPBT) Retained Earnings (2014 - 2026)

Purple Biotech (PPBT) has 13 years of Retained Earnings data on file, last reported at -$171.2 million in Q1 2026.

• On a quarterly basis, Retained Earnings fell 17.93% year-over-year to -$171.2 million in Q1 2026; TTM through Mar 2026 was -$171.2 million, a 17.93% decrease from a year earlier, with the FY2025 full-year figure at -$171.1 million, down 18.24% from the prior year.
• Retained Earnings for Q1 2026 stood at -$171.2 million, roughly flat from -$171.1 million in the prior quarter.
• Over the last five years, Retained Earnings for PPBT reached as high as -$103.2 million in Q1 2022 and fell as low as -$171.2 million in Q1 2026.
• Historically, Retained Earnings has averaged -$136.1 million across 5 years, with a median of -$141.2 million in 2024.
• Across the five-year window, Retained Earnings retreated 22.82% in 2022 and dropped 1.82% in 2025, its largest moves.
• Year by year, Retained Earnings stood at -$117.6 million in 2022, then decreased by 16.91% to -$137.5 million in 2023, then dropped by 5.27% to -$144.7 million in 2024, then retreated by 18.24% to -$171.1 million in 2025, then dropped by 0.05% to -$171.2 million in 2026.
• Per Business Quant data, the three most recent Retained Earnings figures were -$171.2 million in Q1 2026, -$171.1 million in Q4 2025, and -$147.5 million in Q3 2025.